EZH2 and neoplasm: The mutation rate of ARID1A gene in OCCC was 42% and in OEC was 25% (22);Mutations activation the PI3K-AKT pathway, induction of tumorigenesis and allows tumor cell proliferation (17, 18);ARID1A interacted with Enhancer of Zeste 2 Polycomb RepressiveComplex 2 Subunit (EZH2) antagonized EZH2-mediated IFN responsiveness, shape cancer immune phenotype and immunotherapy (21)